树突状细胞-细胞因子诱导的杀伤细胞治疗晚期非小细胞肺癌的疗效分析  

The short-term efficacy of dendritic cell cytokine induced killer cells in the treatment of advanced non-small cell lung cancer

作　　者：刘丽萍[1] 王军[1] 王丽霞[1] 金亚萍[1] 温瑞娟[1] 王丽娜[1] 李伟[1] 

机构地区：[1]内蒙古包头市肿瘤医院肿瘤内科,包头014030

出　　处：《中国肿瘤临床与康复》2016年第2期143-145,共3页Chinese Journal of Clinical Oncology and Rehabilitation

摘　　要：目的探讨自体树突状细胞(DC)-细胞因子诱导的杀伤细胞(CIK)治疗晚期非小细胞肺癌的近期疗效。方法回顾性分析2011年3月至2015年3月收治的采用DC-CIK治疗的46例晚期非小细胞肺癌患者的临床资料。结果 46例患者经过治疗后,近期总有效率为26.1%,疾病控制率为65.2%。治疗后CD3+、CD4+、CD56+和CD4+/CD8+比值均高于治疗前,白细胞介素(IL-2)、IL-12、γ干扰素(IFN-γ)、肿瘤坏死因子α(TNF-α)均高于治疗前,差异均有统计学意义(均P<0.05)。结论 DC-CIK治疗晚期非小细胞肺癌的近期疗效显著,值得临床推广应用。Objective To study the efficacy of dendritic cell cytokine induced killer cells （ DC- CIK） in the treatment of advanced non-small cell lung cancer. Methods A retrospective analysis of clinical data of 46 cases of advanced non-small cell lung cancer treatd by our hospital during March 2011 to March 2015 were conducted. Results After treatment, the recent total effective rate was 26. 1%, disease control rates is 65.2% ; After treatment ,The CD3＋ , CD4＋ ,CD56＋, CD4＋ / CDs ratio are higher than before the treat- ment, IL - 2, IL - 12, IFN - gamma, TNF alpha were higher than before the treatment, difference have sta- tistical significance （P 〈 0.05）. Conclusion DC-CIK treatment of advanced non-small cell lung cancer in the near future curative effect was distinct, and worthy of chnical apphcation.

关 键 词：树突状细胞-细胞因子 癌 非小细胞肺 治疗结果 

分 类 号：R734.2[医药卫生—肿瘤]